Stockscreener 앱 받기
1.45
17.61%
-0.31
시간 외 거래:
1.52
0.07
+4.83%
Clearmind Medicine Inc 주식(CMND)의 최신 뉴스
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ ... - Caledonian Record
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments - Yahoo Finance
Breakouts Watch: Is Clearmind Medicine Inc a strong growth stock - baoquankhu1.vn
Aug Retail: Is Clearmind Medicine Inc stock a buy or sellQuarterly Growth Report & Verified Short-Term Plans - baoquankhu1.vn
Aug Macro: Does Varonis Systems Inc have a competitive edgeJobs Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
Clearmind Medicine registers 17M shares for resale linked to $10M convertible note deal - MSN
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025 - The Manila Times
Clearmind Medicine Inc. Files Annual Report on Form 20-F for Fiscal Year Ended October 31, 2025 - Quiver Quantitative
Clearmind Medicine: Net loss narrowed, but ongoing losses, no revenue, and funding needs raise going concern risk - TradingView
Will Clearmind Medicine Inc. stock deliver shareholder valueDay Trade & Free Long-Term Investment Growth Plans - bollywoodhelpline.com
Clearmind Medicine regains compliance with NASDAQ minimum bid price rule - MSN
Clearmind Medicine (NASDAQ:CMND) Shares Up 0.4% – What’s Next? - Defense World
Clearmind completes treatment for second cohort in AUD drug trial By Investing.com - Investing.com Nigeria
Clearmind announces completion of treatment for second cohort in CMND-100 trial - TipRanks
Clearmind Completes Treatment In 2nd Cohort Of CMND-100 Phase I/IIa Trial In Alcohol Use Disorder - Nasdaq
Clearmind completes treatment for second cohort in AUD drug trial - Investing.com
Clearmind Medicine IncTopline results from second cohort of CMND-100 expected in coming months - marketscreener.com
Clearmind Medicine Inc. Completes Treatment for Second Cohort in Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder | CMND Stock News - Quiver Quantitative
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100 - The Manila Times
6 patients finish Clearmind trial testing new alcohol use disorder drug - Stock Titan
Will Clearmind Medicine Inc. outperform tech stocks2025 Trading Recap & Stepwise Trade Signal Implementation - bollywoodhelpline.com
Aug Final Week: Does Clearmind Medicine Inc stock trade at a discount to peersJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - Bộ Nội Vụ
Risk On: Is Clearmind Medicine Inc a potential multi bagger2025 Valuation Update & Safe Entry Zone Tips - baoquankhu1.vn
Why Clearmind Medicine Inc. stock remains on buy listsTrail vs Road Selection & compare fit, width, and feel - Улправда
Published on: 2026-01-09 01:57:04 - Улправда
Does Clearmind Medicine Inc. (CWY0) stock trade below intrinsic valueQuarterly Investment Review & Scalable Portfolio Growth Methods - Улправда
Will Clearmind Medicine Inc. stock benefit from AI adoptionStock Buy Signals & Target Triple-Digit Stock Opportunities - ulpravda.ru
Surprises Report: Why Clearmind Medicine Inc stock is recommended by analystsChart Signals & Safe Swing Trade Setups - Bộ Nội Vụ
How geopolitical tensions affect Clearmind Medicine Inc. stock2026 world cup usa national team group stage defensive leaders possession football match prediction insights - Улправда
Why retail traders accumulate Clearmind Medicine Inc. (CWY0) stockStop Loss Placement Tips & Build Wealth With Zero-Cost Tools - bollywoodhelpline.com
Portfolio Shifts: Why Clearmind Medicine Inc stock is recommended by analystsRate Cut & Reliable Price Action Trade Plans - moha.gov.vn
Clearmind Medicine (CMND) Stock Analysis Report | Financials & Insights - Benzinga España
Clearmind Medicine Announces the Notice of an International Patent App... - Moscow-Pullman Daily News
Clearmind regains Nasdaq compliance as shares maintain $1 minimum By Investing.com - Investing.com Nigeria
Clearmind regains Nasdaq compliance as shares maintain $1 minimum - Investing.com India
Clearmind Medicine Says Nasdaq Compliance Regained on Minimum Bid Price Rule - MarketScreener
Clearmind Medicine regains compliance with Nasdaq minimum bid price rule - TipRanks
Clearmind Medicine Inc. Regains Compliance with Nasdaq Listing Requirements | CMND Stock News - Quiver Quantitative
Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement - marketscreener.com
Clearmind Medicine highlights key 2025 achievements - MSN
Clearmind advances AUD treatment as phase I/IIa trial progresses By Investing.com - Investing.com Australia
Clearmind advances AUD treatment as phase I/IIa trial progresses - Investing.com
Clearmind Medicine Inc. Reflects on Major Progress in 2025 Clinical Trials for CMND-100 Targeting Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth - Yahoo Finance
Psychedelic: Clearmind completes second cohort enrollment for CMND-100 trial - MSN
San Gabriel Valley Tribune - FinancialContent
Cash from operating activities of Clearmind Medicine Inc. – MUN:CWY - TradingView — Track All Markets
Trading Recap: How strong is Clearmind Medicine Inc. stock balance sheetJuly 2025 Selloffs & Weekly Setup with ROI Potential - moha.gov.vn
How interest rate cuts could boost Clearmind Medicine Inc. stock2025 Geopolitical Influence & Short-Term High Return Ideas - Улправда
0.96%
2.92%
자본화:
|
볼륨(24시간):